Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry

被引:43
作者
Igarashi, K
Hotta, K
Kasuya, F
Abe, K
Sakoda, S
机构
[1] Kobe Gakuin Univ, Fac Pharmaceut Sci, Lab Biochem Toxicol, Nishi Ku, Kobe, Hyogo 6512180, Japan
[2] Kobe Gakuin Univ, High Technol Res Ctr, Nishi Ku, Kobe, Hyogo 6512180, Japan
[3] Osaka Univ, Grad Sch Med, Dept Neurol, Suita, Osaka 5650871, Japan
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 792卷 / 01期
关键词
L-dopa; cabergoline;
D O I
10.1016/S1570-0232(03)00279-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We determined cabergoline and L-dopa in human plasma using liquid chromatography-mass spectrometry with tandem mass spectrometry (LC-MS-MS). The deproteinized plasma samples with organic solvent or acid were analyzed directly by reversed-phase liquid chromatography. Using multiple reaction monitoring (MRM, product ions m/z 381 of m/z 452 for cabergoline and m/z 152 of m/z 198 for L-dopa) on LC-MS-MS with electrospray ionization (ESI), cabergoline and L-dopa in human plasma were determined. Calibration curves of the method showed a good linearity in the range 5-250 pg/ml for cabergoline and 1-200 ng/ml for L-dopa, respectively. The limit of determination was estimated to be approximately 2 pg/ml for cabergoline and approximately 0.1 ng/ml for L-dopa, respectively. The method was applied to the analysis of cabergoline and L-dopa in plasma samples from patients treated with these drugs. The precision of analysis showed coefficients of variation ranging from 3.8% to 10.5% at cabergoline concentration of 13.8-26.2 pg/ml and from 2.9% to 8.9% at an L-dopa concentration of 302.5-522.1 ng/ml in patient plasma. As a result, the procedure proved to be very suitable for routine analysis. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 20 条
[1]  
Allievi C, 1998, RAPID COMMUN MASS SP, V12, P33, DOI 10.1002/(SICI)1097-0231(19980115)12:1<33::AID-RCM68>3.0.CO
[2]  
2-U
[3]   DIFFERENTIAL-EFFECTS OF 3 DOPAMINE-RECEPTOR AGONISTS IN MPTP-TREATED MONKEYS [J].
ARAI, N ;
ISAJI, M ;
MIYATA, H ;
FUKUYAMA, J ;
MIZUTA, E ;
KUNO, S .
JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, 1995, 10 (01) :55-62
[4]   INVIVO INTERACTION OF CABERGOLINE WITH RAT-BRAIN DOPAMINE-RECEPTORS LABELED WITH [H-3] N-N-PROPYLNORAPOMORPHINE [J].
BENEDETTI, MS ;
DOSTERT, P ;
BARONE, D ;
EFTHYMIOPOULOS, C ;
PERETTI, G ;
RONCUCCI, R .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 187 (03) :399-408
[5]   Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection [J].
Blandini, F ;
Martignoni, E ;
Pacchetti, C ;
Desideri, S ;
Rivellini, D ;
Nappi, G .
JOURNAL OF CHROMATOGRAPHY B, 1997, 700 (1-2) :278-282
[6]  
CONSTANZER TV, 1994, J PHARM BIOMED ANAL, V12, P705
[7]  
Dethy S, 1997, CLIN CHEM, V43, P740
[8]   LONG-LASTING PROLACTIN-LOWERING EFFECT OF CABERGOLINE, A NEW DOPAMINE AGONIST, IN HYPERPROLACTINEMIC PATIENTS [J].
FERRARI, C ;
BARBIERI, C ;
CALDARA, R ;
MUCCI, M ;
CODECASA, F ;
PARACCHI, A ;
ROMANO, C ;
BOGHEN, M ;
DUBINI, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :941-945
[9]   Determination of a method for detecting and quantifying azaperone, azaperol and carazolol in pig tissues by liquid chromatography-tandem mass spectrometry [J].
Fluchard, D ;
Kiebooms, S ;
Dubois, M ;
Delahaut, P .
JOURNAL OF CHROMATOGRAPHY B, 2000, 744 (01) :139-147
[10]  
JORI MC, 1990, MOV DISORD S, V5, P62